



## THE BURDEN OF COPD IN CENTRAL & EASTERN EUROPE

Assist. Prof. Maria Kamusheva, M.Pharm, PhD  
Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical  
University-Sofia

### Chronic Obstructive Pulmonary Disease



#### Clinical features

- ▶ A **progressive life-threatening** lung disease;
- ▶ Causes **limitations in lung airflow**;
- ▶ Not curable disease;
- ▶ The **treatment** can relieve symptoms, improve quality of life and reduce the risk of death.
  
- ▶ Substantial and increasing **social and economic implications** in the modern society.



# Chronic Obstructive Pulmonary Disease



## Epidemiological issues

- ▶ Expected to become **the 3rd leading cause** of mortality worldwide in 2030;
- ▶ **Its prevalence varies** across countries;
- ▶ Insufficient officially published **epidemiological data** in some countries;
- ▶ **Further epidemiological studies** should be conducted.



# Chronic Obstructive Pulmonary Disease



## Economic burden

- ▶ Costly disease;
- ▶ Significant economic burden;
- ▶ Its direct and indirect costs present a large share of the total health care expenditure.
- ▶ The costs are placed on the **7<sup>th</sup> position** in the world;
- ▶ **Exacerbations and concomitant diseases** are important factors in the progression of the disease;
- ▶ **Increasing** direct medical and nonmedical **costs**;
- ▶ The higher the **severity** of COPD and **exacerbation rates**, the higher the **health care resources** utilization, number of **hospitalizations** and hospital **cost**.

# Chronic Obstructive Pulmonary Disease



## ***In conclusion***

- ▶ *An increasing need of performing economic evaluation on COPD especially in the conditions of innovative inhalation technologies;*
- ▶ *The results of patients' compliance studies could be used for the purposes of making more precise and valuable economic evaluations.*

